![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merck Research Laboratories, West Point, Pennsylvania (K.K., I.M., D.C., S.M., L.A.W.), Upper Gwynedd, Pennsylvania (N.A.), and Rahway, New Jersey (D.H., M.I., J.A.W.); and SFBC International, Miami, Florida (K.L.)
Raltegravir is a potent human immunodeficiency virus 1 (HIV-1) integrase strand transfer inhibitor that is being developed as a novel anti-AIDS drug. The absorption, metabolism, and excretion of raltegravir were studied in healthy volunteers after a single oral dose of 200 mg (200 µCi) of [14C]raltegravir. Plasma, urine, and fecal samples were collected at specified intervals up to 240 h postdose, and the samples were analyzed for total radioactivity, parent compound, and metabolites. Radioactivity was eliminated in substantial amounts in both urine (32%) and feces (51%). The elimination of radioactivity was rapid, since the majority of the recovered dose was attributable to samples collected through 24 h. In extracts of urine, two components were detected and were identified as raltegravir and the glucuronide of raltegravir (M2), and each accounted for 9% and 23% of the dose recovered in urine, respectively. Only a single radioactive peak, which was identified as raltegravir, was detected in fecal extracts; raltegravir in feces is believed to be derived, at least in part, from the hydrolysis of M2 secreted in bile, as demonstrated in rats. The major entity in plasma was raltegravir, which represented 70% of the total radioactivity, with the remaining radioactivity accounted for by M2. Studies using cDNA-expressed UDP-glucuronosyltransferases (UGTs), form-selective chemical inhibitors, and correlation analysis indicated that UGT1A1 was the main UGT isoform responsible for the formation of M2. Collectively, the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation.
This article has been cited by other articles:
|
|
 |
|
  A. Di Biagio, R. Rosso, M. Siccardi, A. D'Avolio, S. Bonora, and C. Viscoli Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient J. Antimicrob. Chemother., October 1, 2009; 64(4): 874 - 875. [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Hanley, L. A. Wenning, A. Moreau, J. T. Kost, E. Mangin, T. Shamp, J. A. Stone, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2752 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Wenning, W. D. Hanley, D. M. Brainard, A. S. Petry, K. Ghosh, B. Jin, E. Mangin, T. C. Marbury, J. K. Berg, J. A. Chodakewitz, et al. Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2852 - 2856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iwamoto, W. D. Hanley, A. S. Petry, E. J. Friedman, J. T. Kost, S. A. Breidinger, K. C. Lasseter, R. Robson, N. M. Lunde, L. A. Wenning, et al. Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1747 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Laufer, O. G. Paz, A. Di Marco, F. Bonelli, E. Monteagudo, V. Summa, and M. Rowley Quantitative Prediction of Human Clearance Guiding the Development of Raltegravir (MK-0518, Isentress) and Related HIV Integrase Inhibitors Drug Metab. Dispos., April 1, 2009; 37(4): 873 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Vatakis, C. C. Nixon, G. Bristol, and J. A. Zack Differentially Stimulated CD4+ T Cells Display Altered Human Immunodeficiency Virus Infection Kinetics: Implications for the Efficacy of Antiviral Agents J. Virol., April 1, 2009; 83(7): 3374 - 3378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T W Mahungu, M A Johnson, A Owen, and D J Back The impact of pharmacogenetics on HIV therapy Int J STD AIDS, March 1, 2009; 20(3): 145 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iwamoto, L. A. Wenning, A. S. Petry, M. Laethem, M. De Smet, J. T. Kost, S. A. Breidinger, E. C. Mangin, N. Azrolan, H. E. Greenberg, et al. Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4338 - 4343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Anderson, T. N. Kakuda, W. Hanley, J. Miller, J. T. Kost, R. Stoltz, L. A. Wenning, J. A. Stone, R. M. W. Hoetelmans, J. A. Wagner, et al. Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4228 - 4232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Wenning, E. J. Friedman, J. T. Kost, S. A. Breidinger, J. E. Stek, K. C. Lasseter, K. M. Gottesdiener, J. Chen, H. Teppler, J. A. Wagner, et al. Lack of a Significant Drug Interaction between Raltegravir and Tenofovir Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3253 - 3258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Steigbigel, D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, et al. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection N. Engl. J. Med., July 24, 2008; 359(4): 339 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iwamoto, J. T. Kost, G. C. Mistry, L. A. Wenning, S. A. Breidinger, T. C. Marbury, J. A. Stone, K. M. Gottesdiener, D. M. Bloomfield, and J. A. Wagner Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval J. Clin. Pharmacol., June 1, 2008; 48(6): 726 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iwamoto, K. Kassahun, M. D. Troyer, W. D. Hanley, P. Lu, A. Rhoton, A. S. Petry, K. Ghosh, E. Mangin, E. P. DeNoia, et al. Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation J. Clin. Pharmacol., February 1, 2008; 48(2): 209 - 214. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
